Up next

Autoplay

Role of PCSK9 Inhibitors In Diabetes by Dr. Vinaya Simha

1 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Dr. Vinaya Simha is an endocrinologist affiliated with Mayo Clinic Hospital -Rochester Methodist Campus and Saint Marys Hospital with over 23 years of clinical expertise. Dr. Simha is one of the doctors at Mayo Clinic who specializes in Endocrinology, Diabetes, and Metabolism

It is found that hyperlipidemia is responsible for triggering cardiovascular risks. But, there are restricted options for patients who are either intolerant to statin therapy or develop cardiovascular risks in spite of tolerated statin therapy. PCSK9 inhibitors mark the class of emerging lipid-lowering molecules as it blocks the PCSK9 and lowers the LDL cholesterol.

This exclusive commentary illustrates the highlighting aspects of PCSK9 inhibitors for hyperlipidemia.

Show more
0 Comments sort Sort By

Up next

Autoplay